86 filings
8-K
RETA
Reata Pharmaceuticals Inc
26 Sep 23
Termination of a Material Definitive Agreement
5:25pm
8-K
RETA
Reata Pharmaceuticals Inc
21 Sep 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
RETA
Reata Pharmaceuticals Inc
12 Sep 23
Other Events
1:16pm
8-K
RETA
Reata Pharmaceuticals Inc
31 Jul 23
Voting and Support Agreement
7:01am
8-K
RETA
Reata Pharmaceuticals Inc
28 Jul 23
Biogen to Acquire Reata Pharmaceuticals
7:16am
8-K
kxyce
10 Jul 23
Entry into a Material Definitive Agreement
8:08pm
8-K
1f503
20 Jun 23
Entry into a Material Definitive Agreement
4:08pm
8-K
60vsz70in9v9x94q5w
7 Jun 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
oecqz25
10 May 23
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
6:45am
8-K
2p8c6s07 uxqmv69r
1 Mar 23
Amendments to Articles of Incorporation or Bylaws
5:01pm
8-K
vssi745daq6
28 Feb 23
Reata Pharmaceuticals SKYCLARYS™ (Omaveloxolone) Approval Conference Call Script
5:28pm
8-K
xvq31rroifif6g9vc
8 Nov 22
REATA PHARMACEUTICALS, INC. ANNOUNCES third QUARTER 2022 FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT PROGRAMS
6:47am
8-K
whrq3m8pv vzuj3
7 Nov 22
In the Court of Chancery of the State of Delaware
5:05pm
8-K
mb26x7wor
8 Aug 22
REATA PHARMACEUTICALS, INC. ANNOUNCES Second QUARTER 2022 FINANCIAL
6:45am
8-K
dv3lmeud21njki
12 Jul 22
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
4:05pm
8-K
3d5 lk9ef00a
9 Jun 22
Departure of Directors or Certain Officers
4:07pm
8-K
ar8hdwa 8mb1ohizi8lf
10 May 22
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
6:48am
8-K
nx0brmp57l0c2gx
2 Mar 22
Departure of Directors or Certain Officers
4:00pm
8-K
5jnt6io jk119
28 Feb 22
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
6:46am
8-K
coinfinu9hw j5zgy62
7 Feb 22
Departure of Directors or Certain Officers
4:05pm